Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Expansion of clinical pipeline
New XF-73 skin infection clinical programme planned to start in China led by existing partner, China Medical System Holdings Limited
Targeting prevention and treatment of superficial skin infections caused by bacteria
Brighton, United Kingdom – 27 September 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, is pleased to announce that the Company’s China regional partner and investor, China Medical System Holdings Limited (CMS), is establishing a new programme with XF-73 targeting the prevention and treatment of superficial skin infections caused by bacteria.
The programme will be run in China and will be focused on delivering a novel product in the local regulatory environment. The project will be led, managed and funded by CMS. Destiny Pharma will contribute scientific advice as required through a steering committee to the expert dermatology team at CMS. CMS has an extensive portfolio of dermatology assets and an expert understanding of the market and its requirements through its existing sales and marketing infrastructure.
Destiny Pharma has cross-reference rights to data generated from the programme and, in the future, could start a similar skin infection clinical programme focused on commercial territories outside those held by CMS (China and other Asian countries excluding Japan).
Destiny Pharma is currently running its own dermal programme with XF-73 in a different indication targeting the prevention and treatment of serious infections associated with burns and open wounds. This programme is in collaboration with both the US government’s National Institute of Allergy and Infectious Diseases (NIAID), and as part of the Global AMR Innovation Fund (GAMRIF) funded UK-China bilateral partnership to tackle AMR which is managed by Innovate UK. This new CMS initiative adds a further, differentiated product to Destiny Pharma’s pipeline, leveraging off the very strong efficacy, formulation and safety package generated to date by the XF platform.
Neil Clark, Chief Executive Officer of Destiny Pharma said: “We are very pleased to announce the addition of this new XF-73 dermal clinical programme to our portfolio with our partner China Medical System Holdings Limited. We are looking forward to the future development of this programme as well as our other infection prevention assets as we continue to build a high quality, late-stage biotechnology company.”
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
+44 (0) 208 078 4357
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0)20 3705 9321
MC Associates AG
Anne Hennecke / Andreas Burckhardt
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
Forward looking statements
Certain information contained in this announcement, including any information as to the Group’s strategy, plans or future financial or operating performance, constitutes “forward-looking statements”. These forward looking statements may be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “aims”, “plans”, “predicts”, “may”, “will”, “seeks” “could” “targets” “assumes” “positioned” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors concerning, among other things, the Group’s results of operations, financial condition, prospects, growth, strategies and the industries in which the Group operates. The directors of the company believe that the expectations reflected in these statements are reasonable, but may be affected by a number of variables which could cause actual results or trends to differ materially. Each forward-looking statement speaks only as of the date of the particular statement. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future or are beyond the Group’s control. Forward looking statements are not guarantees of future performance. Even if the Group’s actual results of operations, financial condition and the development of the industries in which the Group operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods.